文献速递类风湿关节炎

治疗还是不治疗?临床可疑关节痛中旨在减轻疾病负担的治疗的当前态度:TREAT EARLIER试验参与者与医疗专业人员的调查

To treat or not to treat? Current attitudes on treatment aimed at modifying the disease burden in clinically suspect arthralgia: a survey among participants of the TREAT EARLIER trial and healthcare professionals.
PubMed 文献 · RMD Open · 2023-01-01

该调查纳入TREAT EARLIER试验的临床可疑关节痛(CSA)患者和荷兰风湿病医疗专业人员,了解他们对在关节痛阶段进行1年甲氨蝶呤治疗以减轻疾病负担(而非预防类风湿关节炎)的态度。85%的患者认为该治疗有益,79%会向他人推荐;88%的医疗专业人员倾向于处方1年治疗以长期改善症状和功能,59%认为获益大于副作用等弊端。

要点

  • 85%的试验参与者认为1年治疗在症状性高危阶段有益,79%会向类似关节痛者推荐1年甲氨蝶呤疗程。
  • 三分之二的CSA患者认为预防类风湿关节炎与改善疾病负担同等重要。
  • 88%的医疗专业人员倾向于给CSA患者处方1年治疗以长期改善症状和功能,59%认为获益大于弊端。

核心结论

  • CSA患者和风湿病医生中相当一部分人愿意开始1年治疗以长期改善症状和功能,而不预防类风湿关节炎。
  • 这强调需要更多研究优化高危个体的治疗方案和疾病监测,以促进未来此类治疗决策,同时避免可能弊大于利的干预(无论有限期还是长期)。

研究设计与样本

  • 对参与TREAT EARLIER试验的CSA患者(作为经验专家)在告知试验结果后完成匿名问卷,调查其对CSA阶段治疗的态度。
  • 对荷兰风湿病医疗专业人员采用相同方法进行调查。

主要发现

  • 大多数试验参与者(85%)认为TREAT EARLIER试验中发现的1年治疗效果在症状性高危阶段有益。
  • 79%的试验参与者会向有关节痛类似的其他患者推荐1年甲氨蝶呤疗程。
  • 三分之二的试验参与者表示在CSA阶段预防类风湿关节炎和改善疾病负担是同等重要的治疗目标。
  • 大多数医疗专业人员(88%)倾向于给CSA患者处方1年治疗,旨在长期改善症状和功能,而不预防类风湿关节炎发展。
  • 59%的医疗专业人员认为1年甲氨蝶呤疗程的获益大于弊端(例如副作用)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: While awaiting therapies accomplishing rheumatoid arthritis (RA)-prevention in individuals at-risk, recent evidence supports that a 1-year methotrexate treatment may lead to sustained reduction in disease burden and subclinical joint inflammation in patients with clinically suspect arthralgia (CSA). We aimed to study the previously unexplored attitudes of CSA patients and rheumatologists on 1-year DMARD treatment in the arthralgia phase to reduce the disease burden, while not preventing RA. METHODS: CSA patients who participated in the TREAT EARLIER trial, thus being expert by experience, were informed on the trial results. Thereafter they completed an anonymous questionnaire about their attitudes on treatment in the CSA phase. We used the same approach for Dutch healthcare professionals in rheumatology. RESULTS: The majority of trial participants (85%) considered the effects of the 1-year treatment as found in the TREAT EARLIER trial, beneficial in the symptomatic at-risk stage. 79% would recommend a 1-year methotrexate course to others with comparable joint complaints. Two-thirds indicated RA prevention and improving disease burden to be equally important treatment goals in the CSA phase. Most healthcare professionals (88%) were inclined to prescribe 1-year treatment to CSA patients aimed at long-term improvement of symptoms and functioning, while not preventing RA development. 59% believed the profits of a 1-year methotrexate course to outweigh disadvantages, for example, side effects. CONCLUSIONS: A considerable willingness exists among CSA patients and rheumatologists to start a 1-year treatment resulting in long-term improvement of symptoms and functioning, while not preventing RA. This emphasises the need for more research optimising treatment regimens and disease monitoring in individuals at-risk to facilitate such treatment decisions in the future, while avoiding an intervention, either limited or for a prolonged period, which may have harms that outweigh benefits. TRIAL REGISTRATION NUMBER: The Netherlands Trials Registry (NTR4853-trial-NL4599). EudraCT number: NL2014-004472-35.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Krijbolder DI, Khidir SJH, van der Helm-van Mil AH, et al. To treat or not to treat? Current attitudes on treatment aimed at modifying the disease burden in clinically suspect arthralgia: a survey among participants of the TREAT EARLIER trial and healthcare professionals. RMD Open. 2023. PMID: 37532468. doi:10.1136/rmdopen-2023-003031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。